Fulgent Genetics (NASDAQ:FLGT - Get Free Report) had its price target reduced by investment analysts at Piper Sandler from $22.00 to $16.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. Piper Sandler's price target would suggest a potential downside of 13.93% from the company's current price.
Separately, StockNews.com cut shares of Fulgent Genetics from a "hold" rating to a "sell" rating in a research note on Wednesday, November 27th.
Check Out Our Latest Stock Analysis on FLGT
Fulgent Genetics Trading Up 3.9 %
FLGT traded up $0.69 during trading on Tuesday, reaching $18.59. 813,378 shares of the company's stock were exchanged, compared to its average volume of 202,350. Fulgent Genetics has a one year low of $14.57 and a one year high of $25.11. The firm has a fifty day moving average price of $17.14 and a two-hundred day moving average price of $19.26. The stock has a market capitalization of $573.11 million, a PE ratio of -3.37 and a beta of 1.54.
Insider Buying and Selling
In other news, CFO Paul Kim bought 100,000 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was acquired at an average price of $15.96 per share, with a total value of $1,596,000.00. Following the completion of the purchase, the chief financial officer now directly owns 348,282 shares of the company's stock, valued at approximately $5,558,580.72. This represents a 40.28 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 31.76% of the stock is owned by insiders.
Institutional Trading of Fulgent Genetics
A number of institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC lifted its stake in shares of Fulgent Genetics by 45.5% in the 4th quarter. GAMMA Investing LLC now owns 2,133 shares of the company's stock valued at $39,000 after purchasing an additional 667 shares during the period. Point72 DIFC Ltd bought a new stake in Fulgent Genetics in the third quarter worth approximately $46,000. Russell Investments Group Ltd. lifted its stake in Fulgent Genetics by 267.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,693 shares of the company's stock valued at $50,000 after buying an additional 1,960 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Fulgent Genetics in the fourth quarter valued at approximately $57,000. Finally, State of Wyoming bought a new position in shares of Fulgent Genetics during the 4th quarter worth approximately $57,000. Institutional investors own 48.06% of the company's stock.
About Fulgent Genetics
(
Get Free Report)
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Featured Stories
Before you consider Fulgent Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulgent Genetics wasn't on the list.
While Fulgent Genetics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
